Quang T Nguyen1, Eun Joo Lee2, Melinda Gingman Huang2, Young In Park2, Aashish Khullar3, Raymond A Plodkowski4. 1. Medical Director, Las Vegas Endocrinology; Clinical Associate Professor, Clinical Education, Arizona College of Osteopathic Medicine; Adjunct Associate Professor of Endocrinology, Touro University Nevada. 2. Osteopathic Medical Student, Touro University Nevada, Henderson. 3. Medical Resident, University of Nevada, Reno, School of Medicine. 4. Endocrinologist, Scripps Green Hospital, San Diego, CA.
Abstract
BACKGROUND: Thyroid cancer is the most common malignancy of the endocrine system, representing 3.8% of all new cancer cases in the United States and is the ninth most common cancer overall. The American Cancer Society estimates that 62,450 people in the United States will be diagnosed with thyroid cancer in 2015, and 1950 deaths will result from the disease. OBJECTIVE: To review the current approach to the diagnosis and treatment of patients with thyroid cancer. DISCUSSION: Over the past 3 decades, there has been a dramatic increase in the number of people diagnosed with thyroid cancer, which may be attributable to the wide use of imaging studies, including ultrasounds, computed tomography, magnetic resonance imaging, and positron emission tomography scans that incidentally detect thyroid nodules. Thyroid cancer is divided into several main types, with papillary thyroid cancer being the most common. The treatment options for patients with thyroid cancer include the surgical removal of the entire thyroid gland (total thyroidectomy), radioactive iodine therapy, and molecular-targeted therapies with tyrosine kinase inhibitors. This article summarizes the diagnosis and treatment of thyroid cancer, with recommendations from the American Thyroid Association regarding thyroid nodules and differentiated thyroid cancer. Recently approved drugs and treatment trends are also explored. CONCLUSION: The prognosis and treatment of thyroid cancer depend on the tumor type and its stage at the time of diagnosis. Many thyroid cancers remain stable, microscopic, and indolent. The increasing treatment options for patients with thyroid cancer, including therapies that were recently approved by the US Food and Drug Administration, have kept the mortality rate from this malignancy low, despite the increase in its incidence. Early diagnosis and appropriate treatment can improve prognosis and reduce mortality.
BACKGROUND:Thyroid cancer is the most common malignancy of the endocrine system, representing 3.8% of all new cancer cases in the United States and is the ninth most common cancer overall. The American Cancer Society estimates that 62,450 people in the United States will be diagnosed with thyroid cancer in 2015, and 1950 deaths will result from the disease. OBJECTIVE: To review the current approach to the diagnosis and treatment of patients with thyroid cancer. DISCUSSION: Over the past 3 decades, there has been a dramatic increase in the number of people diagnosed with thyroid cancer, which may be attributable to the wide use of imaging studies, including ultrasounds, computed tomography, magnetic resonance imaging, and positron emission tomography scans that incidentally detect thyroid nodules. Thyroid cancer is divided into several main types, with papillary thyroid cancer being the most common. The treatment options for patients with thyroid cancer include the surgical removal of the entire thyroid gland (total thyroidectomy), radioactive iodine therapy, and molecular-targeted therapies with tyrosine kinase inhibitors. This article summarizes the diagnosis and treatment of thyroid cancer, with recommendations from the American Thyroid Association regarding thyroid nodules and differentiated thyroid cancer. Recently approved drugs and treatment trends are also explored. CONCLUSION: The prognosis and treatment of thyroid cancer depend on the tumor type and its stage at the time of diagnosis. Many thyroid cancers remain stable, microscopic, and indolent. The increasing treatment options for patients with thyroid cancer, including therapies that were recently approved by the US Food and Drug Administration, have kept the mortality rate from this malignancy low, despite the increase in its incidence. Early diagnosis and appropriate treatment can improve prognosis and reduce mortality.
Authors: Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958
Authors: Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski Journal: Am Health Drug Benefits Date: 2015-02
Authors: G Riesco-Eizaguirre; P Gutiérrez-Martínez; M A García-Cabezas; M Nistal; P Santisteban Journal: Endocr Relat Cancer Date: 2006-03 Impact factor: 5.678
Authors: Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky Journal: J Natl Cancer Inst Date: 2003-04-16 Impact factor: 13.506
Authors: Melissa M Boltz; Christopher S Hollenbeak; Eric Schaefer; David Goldenberg; Brian D Saunders Journal: Surgery Date: 2013-08-22 Impact factor: 3.982
Authors: Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier Journal: Am J Nucl Med Mol Imaging Date: 2020-02-25
Authors: Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski Journal: Am Health Drug Benefits Date: 2015-02
Authors: Amblessed E Onuma; Eliza W Beal; Fadi Nabhan; Tasha Hughes; William B Farrar; John Phay; Matthew D Ringel; Richard T Kloos; Lawrence A Shirley Journal: Ann Surg Oncol Date: 2019-02-28 Impact factor: 5.344
Authors: Elena Salamanca-Fernández; Miguel Rodriguez-Barranco; Yoe-Ling Chang-Chan; Daniel Redondo-Sánchez; Santiago Domínguez-López; Eloísa Bayo; Dariusz Narankiewicz; José Expósito; María José Sánchez Journal: Endocrine Date: 2018-07-24 Impact factor: 3.633
Authors: Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista M D La Perle; Laura Boucai; Lawrence S Kirschner Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958